TG Therapeutics, Inc.TG Therapeutics, Inc.TG Therapeutics, Inc.

TG Therapeutics, Inc.

No trades
See on Supercharts
Market capitalization
‪2.13 B‬USD
‪12.67 M‬USD
‪233.66 M‬USD
‪139.66 M‬
Beta (1Y)
3.40

About TG Therapeutics, Inc.

CEO
Michael Sean Weiss
Headquarters
Morrisville
Employees (FY)
264
Founded
1993
ISIN
US88322Q1085
FIGI
BBG000FVZQY1
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of TGTX is 14.54 USD — it has increased by 5.17% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TG Therapeutics, Inc. stocks are traded under the ticker TGTX.
TG Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
TGTX stock is 5.85% volatile and has beta coefficient of 3.40. Check out the list of the most volatile stocks — is TG Therapeutics, Inc. there?
One year price forecast for TG Therapeutics, Inc. has a max estimate of 45.00 USD and a min estimate of 7.00 USD.
TGTX earnings for the last quarter are 0.73 USD whereas the estimation was 0.06 USD which accounts for ‪1.18 K‬% surprise. Estimated earnings for the next quarter are −0.10 USD. See more details about TG Therapeutics, Inc. earnings.
TG Therapeutics, Inc. revenue for the last quarter amounts to ‪165.82 M‬ USD despite the estimated figure of ‪23.91 M‬ USD. In the next quarter revenue is expected to reach ‪40.06 M‬ USD.
Yes, you can track TG Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TGTX stock has fallen by 1.86% compared to the previous week, the month change is a 3.42% fall, over the last year TG Therapeutics, Inc. has showed a 30.00% decrease.
TGTX net income for the last quarter is ‪−14.42 M‬ USD, while the quarter before that showed ‪113.93 M‬ USD of net income which accounts for −112.65% change. Track more TG Therapeutics, Inc. financial stats to get the full picture.
Today TG Therapeutics, Inc. has the market capitalization of ‪2.13 B‬, it has increased by 3.67% over the last week.
No, TGTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TGTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
TGTX reached its all-time high on Mar 14, 2000 with the price of 149411.41 USD, and its all-time low was 0.96 USD and was reached on Dec 29, 2011.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 264.00 employees. See our rating of the largest employees — is TG Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TG Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TG Therapeutics, Inc. stock shows the sell signal. See more of TG Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on TG Therapeutics, Inc. future price: according to them, TGTX price has a max estimate of 45.00 USD and a min estimate of 7.00 USD. Read a more detailed TG Therapeutics, Inc. forecast: see what analysts think of TG Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG Therapeutics, Inc. EBITDA is ‪21.06 M‬ USD, and current EBITDA margin is 9.01%. See more stats in TG Therapeutics, Inc. financial statements.